All In Biotech

Drug Trial Radar · NCT00872729

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

A Pilot Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cysteamine Bitartrate (Cystagon®) in Patients With Nephropathic Cystinosis

Last checked: Nov 20, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

9

Actual

Start

May 2009

Primary completion

Oct 2009

Study completion Oct 2009

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Mar 31, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cystinosis is an inheritable disease that if untreated, results in kidney failure as early as the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate) which must be taken every six hours for the rest of the patient's life to prevent complications of cystinosis. RP103 is a formulation of cysteamine bitartrate that is being studied to see if it may be able to be given less frequently, once every 12 hours, and have similar results.

Conditions

  • Cystinosis

Interventions

  • Cystagon®Drug

    Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg. Duration of Treatment and Dose: Reference Period up to four doses Q6H.

  • RP103Drug

    Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg. Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma Pharmacokinetic Parameter: Cmax of CysteamineTime frame: 12 hours post RP103 dosing and 7 hours post 1st Cystagon® dosing
  2. Plasma Pharmacokinetic Parameter: Tmax of CysteamineTime frame: 12 hours post RP103 dosing and 7 hours post 1st Cystagon® dosing
  3. Plasma Pharmacokinetic Parameter: AUC(0-t) of CysteamineTime frame: 12 hours post RP103 dosing and 6 hours post 1st Cystagon® dosing
  4. Pharmacodynamic Parameter: Changes of White Blood Cell (WBC) Cystine Level From BaselineTime frame: up to 12 hours post Cystagon® dosing and RP103 dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California San Diego Medical Center

    San Diego, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.